SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

25 May 2023 Evaluate
The company witnessed a 23.68% growth in the revenue at Rs. 5635.57 millions for the quarter ended March 2023 as compared to Rs. 4556.57 millions during the year-ago period.Net Profit of the company move down -68.88% to Rs. 623.97  millions from Rs. 2005.04 millions  in the same quarter last year.Operating Profit saw a handsome growth to 1458.13 millions from 1026.63 millions in the quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 5635.57 4556.57 23.68 18544.96 19790.03 -6.29 18544.96 19790.03 -6.29
Other Income 263.78 848.29 -68.90 840.66 1234.85 -31.92 840.66 1234.85 -31.92
PBIDT 1458.13 1026.63 42.03 1825.43 2001.15 -8.78 1825.43 2001.15 -8.78
Interest 429.01 215.47 99.10 1386.82 742.41 86.80 1386.82 742.41 86.80
PBDT 879.12 811.16 8.38 288.61 1258.74 -77.07 288.61 1258.74 -77.07
Depreciation 227.12 244.09 -6.95 936.21 1043.66 -10.30 936.21 1043.66 -10.30
PBT 652.00 567.07 14.98 -647.60 215.08 -401.10 -647.60 215.08 -401.10
TAX 28.03 -1437.97 -101.95 -694.42 -1586.80 -56.24 -694.42 -1586.80 -56.24
Deferred Tax 258.12 146.74 75.90 -195.99 -2.09 9277.51 -195.99 -2.09 9277.51
PAT 623.97 2005.04 -68.88 46.82 1801.88 -97.40 46.82 1801.88 -97.40
Equity 903.03 897.90 0.57 903.03 897.90 0.57 903.03 897.90 0.57
PBIDTM(%) 25.87 22.53 14.84 9.84 10.11 -2.66 9.84 10.11 -2.66

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×